alexa Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study.
Nephrology

Nephrology

Journal of Nephrology & Therapeutics

Author(s): Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE,

Abstract Share this page

Abstract Few data exist to guide treatment of anemic hemodialysis patients with high ferritin and low transferrin saturation (TSAT). The Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) trial was designed to evaluate the efficacy of intravenous ferric gluconate in such patients. Inclusion criteria were hemoglobin or=225 IU/kg per wk or >or=22,500 IU/wk. Patients with known infections or recent significant blood loss were excluded. Participants (n=134) were randomly assigned to no iron (control) or to ferric gluconate 125 mg intravenously with eight consecutive hemodialysis sessions (intravenous iron). At randomization, epoetin was increased 25\% in both groups; further dosage changes were prohibited. At 6 wk, hemoglobin increased significantly more (P=0.028) in the intravenous iron group (1.6 +/- 1.3 g/dl) than in the control group (1.1 +/- 1.4 g/dl). Hemoglobin response occurred faster (P=0.035) and more patients responded after intravenous iron than in the control group (P=0.041). Ferritin 800 ng/ml had no relationship to the magnitude or likelihood of responsiveness to intravenous iron relative to the control group. Similarly, the superiority of intravenous iron compared with no iron was similar whether baseline TSAT was above or below the study median of 19\%. Ferritin decreased in control subjects (-174 +/- 225 ng/ml) and increased after intravenous iron (173 +/- 272 ng/ml; P<0.001). Intravenous iron resulted in a greater increase in TSAT than in control subjects (7.5 +/- 7.4 versus 1.8 +/- 5.2\%; P<0.001). Reticulocyte hemoglobin content fell only in control subjects, suggesting worsening iron deficiency. Administration of ferric gluconate (125 mg for eight treatments) is superior to no iron therapy in anemic dialysis patients receiving adequate epoetin dosages and have a ferritin 500 to 1200 ng/ml and TSAT
  • DOI: 10.1681/ASN.2006091034
  • This article was published in J Am Soc Nephrol and referenced in Journal of Nephrology & Therapeutics

    Relevant Expert PPTs

    Relevant Speaker PPTs

    Recommended Conferences

    • 16th International Conference on Nephrology
      NOVEMBER 02-03, 2017 Atlanta, USA

    Relevant Topics

    Peer Reviewed Journals
     
    Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
    International Conferences 2017-18
     
    Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

    Contact Us

    Agri, Food, Aqua and Veterinary Science Journals

    Dr. Krish

    [email protected]

    1-702-714-7001 Extn: 9040

    Clinical and Biochemistry Journals

    Datta A

    [email protected]

    1-702-714-7001Extn: 9037

    Business & Management Journals

    Ronald

    [email protected]

    1-702-714-7001Extn: 9042

    Chemical Engineering and Chemistry Journals

    Gabriel Shaw

    [email protected]

    1-702-714-7001 Extn: 9040

    Earth & Environmental Sciences

    Katie Wilson

    [email protected]

    1-702-714-7001Extn: 9042

    Engineering Journals

    James Franklin

    [email protected]

    1-702-714-7001Extn: 9042

    General Science and Health care Journals

    Andrea Jason

    [email protected]

    1-702-714-7001Extn: 9043

    Genetics and Molecular Biology Journals

    Anna Melissa

    [email protected]

    1-702-714-7001 Extn: 9006

    Immunology & Microbiology Journals

    David Gorantl

    [email protected]

    1-702-714-7001Extn: 9014

    Informatics Journals

    Stephanie Skinner

    [email protected]

    1-702-714-7001Extn: 9039

    Material Sciences Journals

    Rachle Green

    [email protected]

    1-702-714-7001Extn: 9039

    Mathematics and Physics Journals

    Jim Willison

    [email protected]

    1-702-714-7001 Extn: 9042

    Medical Journals

    Nimmi Anna

    [email protected]

    1-702-714-7001 Extn: 9038

    Neuroscience & Psychology Journals

    Nathan T

    [email protected]

    1-702-714-7001Extn: 9041

    Pharmaceutical Sciences Journals

    John Behannon

    [email protected]

    1-702-714-7001Extn: 9007

    Social & Political Science Journals

    Steve Harry

    [email protected]

    1-702-714-7001 Extn: 9042

     
    © 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
    adwords